Content Type: Commentary & Opinion

Patient Assistance Programs and the Anti-Kickback Statute: Charting a Pathway Forward

March 16, 2026

Incentives for Drug Development—The Curious Case of Colchicine

March 16, 2026

Orphan Drug Designation and Exclusivity for “Same Drugs”

March 16, 2026

Will Inter Partes Review Speed US Generic Drug Entry?

March 16, 2026

Product-Specific Regulatory Pathways to Approve Generic Drugs: The Need for Follow-Up Studies to Ensure Safety and Effectiveness

March 16, 2026

Value-Based Pricing and State Reform of Prescription Drug Costs

March 16, 2026

A New Approach to Treat Childhood Leukemia: Novartis’ CAR-T Therapy

March 16, 2026

Ensuring Patient Privacy in Data Sharing for Postapproval Research

March 16, 2026

Promoting Confidence in Cost-Effectiveness Analyses

March 16, 2026

The 21st Century Cures Act: Opportunities and Challenges

March 16, 2026

FDA Approval of Desmopressin for Nocturia

March 16, 2026

Reinforcing the Social Compromise of Accelerated Approval

March 16, 2026